SARI67, 69–71, Germany AMR Public Organism Hospital Antimicrobial S. aureus n/a 73, 75, (40 German funding ICUs usage, reported 130, 234–236 ICUs) and (German incidence and as (commenced antibiotic susceptibility staphylococci DDD/1000 collecting testing of E. faecalis patient days; prospective bacterial E. faecium data from ICUs isolates against P. aeruginosa participating in antibiotics E. cloacae publications the German Citrobacter spp. S. marcescens System (KISS); A. baumannii similar to S. maltophilia ICARE [US]) S. pneumoniae E. coli K. pneumoniae MABUSE Germany Public n/a Ambulatory n/a n/a n/a WHO DDDs network9, 237 funding and hospital are used in (German data addition to and AMR prescribed daily doses; publications
SARI67, 69–71, 73, 75, 130, 234–236 (commenced collecting prospective data from ICUs participating in the German System (KISS); similar to ICARE [US]) Germany (40 German ICUs) AMR and antibiotic Public funding (German Organism Hospital ICUs Antimicrobial usage, incidence and susceptibility testing of bacterial isolates against antibiotics S. aureus staphylococci E. faecalis E. faecium P. aeruginosa E. cloacae Citrobacter spp. S. marcescens A. baumannii S. maltophilia S. pneumoniae E. coli K. pneumoniae n/a reported as DDD/1000 patient days; publications MABUSE network9, 237 Germany and AMR Public funding (German n/a Ambulatory and hospital data n/a n/a n/a WHO DDDs are used in addition to prescribed daily doses; publications
National-surveillance-and-reporting-of-antimicrobial-resistance-and-antibiotic-usage-for-human-health-in-Australia.docx